Abstract:All-trans-retinoic acid (ATRA), the biologically most active metabolite of vitamin A, plays a major role in the regulation of cellular differentiation and proliferation, and it is also an important pharmacological agent particularly used in the treatment of cancer, skin, neurodegenerative and autoimmune diseases. However, ATRA is very easy to be metabolized into 4-hydroxyl-RA in vivo by CYP26A1, an inducible cytochrome P450 enzyme, eventually into more polar metabolites. Therefore, it is vital to develop specific retinoic acid metabolism blocking agents (RAMBAs) to inhibit the metabolic enzyme CYP26A1 in the treatment of relevant diseases aforementioned.In this study, CYP26A1 and its interactions with retinoic acid-competitive metabolism blocking agents were investigated by a combined ligand- and structure-based approach. First, since the crystal structure of CYP26A1 protein has not been determined, we constructed the 3D structure of CYP26A1 using homology modeling. In order to achieve a deeper insight into the mode of action of RAMBAs in the active site, the molecular superimposition model and the common feature pharmacophore model were constructed, and molecular docking was performed. The molecular superimposition model is composed of three features: the main chain groups, side chain groups, and azole groups. The common feature pharmacophore model consists of five chemical features: four hydrophobic groups and one hydrogen acceptor (HHHHA). The results of molecular docking show that the characteristic groups of RAMBAs were mapped into three different active pockets, respectively.A structure-activity relationship (SAR) was obtained by a combination of the molecular superimposition and docking results with the pharmacophore model. This study gives more insight into the interaction model inside the CYP26A1 active site and provides guidance for the design of more potent and possibly more selective RAMBAs. (C) 2014 Elsevier Inc. All rights reserved.

Determinants of retinoid X receptor transcriptional antagonism.

Structural Basis for Retinoic X Receptor Repression on the Tetramer

The Effect of Antagonists on the Conformational Exchange of the Retinoid X Receptor Alpha Ligand-Binding Domain

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

Retinoid-dependent in vitro transcription mediated by the RXR/RAR heterodimer.

Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.

Structural basis for the full and partial agonist activities of retinoid X receptor α ligands with an iso-butoxy and an isopropyl group

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

Retinoid X receptor ligands: a patent review (2007 – 2013)

Discovery and Design of Retinoic Acid Receptor and Retinoid X Receptor Class- and Subtype-Selective Synthetic Analogs of All-Trans-retinoic Acid and 9-Cis-retinoic Acid.

A Structure-based Approach to Retinoid X Receptor-α Inhibition

Derivation of a Retinoid X Receptor Scaffold from Peroxisome Proliferator‐Activated Receptor Γ Ligand 1‐Di(1h‐indol‐3‐yl)methyl‐4‐trifluoromethylbenzene

The retinoid X receptor has a critical role in synthetic rexinoid-induced increase in cellular all- trans -retinoic acid

Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site.

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

sp2-bridged diaryl retinoids: Effects of bridge-region substitution on retinoid x receptor (RXR) selectivity

Molecular Basis of the Interaction Between IGFBP-3 and Retinoid X Receptor: Role in Modulation of RAR-signaling

Mutations That Alter Ligand-induced Switches and Dimerization Activities in the Retinoid X Receptor

Regulation of the Nongenomic Actions of Retinoid X Receptor-Α by Targeting the Coregulator-Binding Sites

Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB)